Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News
  • Published:

Ustekinumab poised to enter the psoriasis market

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Centocor's mAb Stelara is the first dual-action drug aimed at the p40 subunit of the IL-12 and IL-23 cytokines to treat severe plaque psoriasis.

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Schmidt, C. Ustekinumab poised to enter the psoriasis market. Nat Biotechnol 26, 1317–1318 (2008). https://doi.org/10.1038/nbt1208-1317a

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nbt1208-1317a

This article is cited by

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing